"Unlike a one-time surge, demand compounds over time as new patients start to layer on top of a growing base of ongoing users, making long-term capacity planning structurally more difficult." Already, GLP-1 drugs are forcing companies to adapt not just to a new product, but to a sustained shift in consumer behavior and healthcare demand that touches food and pharmaceutical supply chains simultaneously
Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R et al (2022) Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis
Las farmacias de compuestos suelen mezclar, alterar o combinar ingredientes de medicamentos para satisfacer las necesidades especficas de un paciente
What does clinical evidence say about GLP-1 dosing and efficacy
The PubMed search returned 98 records